Arcutis Biotherapeutics Inc. (ARQT) anticipates that its product revenue for the fourth quarter of 2024 will reach approximately $63 million. This reflects a significant year-over-year increase of about 366% compared to the same period in 2023, and a quarter-over-quarter rise of roughly 41% relative to the third quarter of 2024.
The revenue surge in the fourth quarter was largely due to heightened demand across all indications for ZORYVE (roflumilast), with the Gross-to-Net (GTN) adjustment remaining stable compared to the previous quarter.
Arcutis has announced that it will release the complete financial results for both the fourth quarter and the full year of 2024, along with a business update, on Tuesday, February 25, 2025, following the closure of the U.S. financial markets.
